6533b858fe1ef96bd12b5a9c
RESEARCH PRODUCT
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
Isaac DreyfusJay GiriJay GiriJay GiriDominic P. FranceseYu HuAlfonso TafurAlfonso TafurLaurent BertolettiSahil A. ParikhJohn W. EikelboomBehnood BikdeliBehnood BikdeliMary CushmanEmmanuel J. FavaloroAnna FalangaAjay J. KirtaneSanjum S. SethiJohn R. BurtonStavros KonstantinidesMarc CarrierLiang V. TangAlex C. SpyropoulosC. Michael GibsonC. Michael GibsonMartin B. LeonJeffrey I. WeitzEvangelos DimakakosKevin J. ClerkinJoshua A. BeckmanGregory PiazzaGregory PiazzaGiuseppe LippiGregg W. StoneJawed FareedClaire MclintockMahesh V. MadhavanBeverley J. HuntJaya BatraTaylor ChuichYutao GuoYutao GuoWalter AgenoHarlan M. KrumholzMohammad MadjidKartik SehgalKartik SehgalGregory Y.h. LipGregory Y.h. LipSamuel Z. GoldhaberSamuel Z. GoldhaberSam SchulmanSam SchulmanManuel MonrealShayan Nabavi NouriGeoffrey D. BarnesNir UrielIsabelle QuéréElissa DrigginCaroline Der NigoghossianIdo WeinbergDavid JiménezStephan RosenkranzAakriti GuptaAakriti GuptaSaurav Chatterjeesubject
0301 basic medicinecoronavirusAnti-Inflammatory AgentsReview Article030204 cardiovascular system & hematologymedicine.disease_causelaw.inventioncovid190302 clinical medicineRandomized controlled triallawAntithromboticPandemicViralanticoagulationCoronavirusGlycosaminoglycansAnimals; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; Fibrinolytic Agents; Glycosaminoglycans; Hemostasis; Humans; Inflammation; Pandemics; Platelet Aggregation Inhibitors; Pneumonia Viral; Thrombosiscoronavirus 2immunomodulatorHematologyHeparinThrombosisantithrombinCoronavirus Infectionsmedicine.drugmedicine.medical_specialtyPneumonia Viralcoronavirus disease 2019 thrombosis inflammation fibrinolytic therapy anticoagulation immunomodulator antithrombin thrombomodulinAntiviral Agents03 medical and health sciencescoronavirus disease 2019BetacoronavirusFibrinolytic AgentsmedicineAnimalsHumansthrombosis COVID-19 coronavirusDosingIntensive care medicinePandemicsthrombosisInflammationHemostasisbusiness.industrySARS-CoV-2AnticoagulantsCOVID-19ThrombosisPneumoniathrombomodulinmedicine.diseaseReview articleCOVID-19 Drug Treatment030104 developmental biologyinflammationfibrinolytic therapybusinessPlatelet Aggregation Inhibitorsdescription
AbstractCoronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-07-01 | Thrombosis and haemostasis |